Immune Checkpoint Inhibitors: Trends and Market Dynamics | Special Topics | G7 – 2020

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of agents targeting checkpoint blockade continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging immune checkpoint inhibitors and analyzes the market trends and dynamics in a range of oncology indications.


  • What is the timeline and current landscape for approved immune checkpoint inhibitors? What are the trends in each key oncology indication?
  • How will emerging immune checkpoint inhibitors be positioned in the market? How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging immune checkpoint inhibitors by brand, indication, combination type, and geography? How will the market evolve over the 2020-2030 forecast period?


United States, EU5, Japan.


Drug-treated patient populations by brand, indication, combination type, and geography for indications for which immune checkpoint inhibitors are approved or forecast for approval.


10-year, annualized, drug-level sales of immune checkpoint inhibitors through 2030, segmented by indication, combination type, and geography.


Currently approved agents targeting PD-1, PD-L1, and CTLA-4.


Phase III/PR.


Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in relevant oncology indications

Login to access report

launch Related Market Assessment Reports